Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.34B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 9.92M
Average 4.07M
Returns on capital
Nuvation Bio Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-66.9%
avg -18.0%
ROIC
-41.0%
avg 54.1%
ROA
-34.4%
avg -106.6%
Analysis
ROA is currently the strongest return metric at -34.4% versus its period average of -106.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David T. Hung | Founder, President, Chief Executive Officer & Chairman | USD 1.2M | 68 | — | — |
Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | USD 810.02K | 48 | 54.13K | 0.02% |
Gary Hattersley | Chief Scientific Officer | USD 805.8K | 59 | 0 | <0.01% |
Colleen Sjogren | Chief Commercial Officer | USD 615.84K | 55 | 748.13K | 0.22% |
David C. Hanley | Chief Technical Operations Officer | USD 586.04K | 56 | 748.13K | 0.22% |
Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | — | 47 | 68.14K | 0.02% |
Robert DeVita | Vice President of Corporate Development & Investor Relations | — | — | — | — |
Kerry A. Wentworth | Chief Regulatory Officer | — | 53 | — | — |
Stacy Markel | Chief People Officer | — | 61 | 32.59K | <0.01% |
Stephen Dang | Chief Legal Officer & Corporate Secretary | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$118,250.00
Sells
14
$8.61M
Net Transaction Value
−$8.49M
Net selling
Most Active
Liu Dongfang
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 19, 26Aug 19, 2026 | Hattersley Gary Direct | Sell | $709.2K$709,240.00 |
| Jun 23, 26Jun 23, 2026 | Markel Stacy Direct | Sell | $753.2K$753,187.50 |
| Jun 23, 26Jun 23, 2026 | Wentworth Kerry Direct | Sell | $379.2K$379,190.70 |
| Jun 23, 26Jun 23, 2026 | Sauvage Philippe Direct | Sell | $286.4K$286,370.28 |
| Jun 9, 26Jun 9, 2026 | Mashal Robert Indirect | Buy | $118.3K$118,250.00 |
| Apr 17, 26Apr 17, 2026 | Wentworth Kerry Direct | Sell | $184.3K$184,279.20 |
| Apr 17, 26Apr 17, 2026 | Liu Dongfang Direct | Sell | $251K$251,000.00 |
| Apr 6, 26Apr 6, 2026 | Wentworth Kerry Direct | Sell | $903.6K$903,560.00 |
| Dec 1, 25Dec 1, 2025 | Liu Dongfang Direct | Sell | $1.2M$1,173,255.00 |
| Nov 26, 25Nov 26, 2025 | Liu Dongfang Direct | Sell | $80K$80,000.00 |
1–10 of 15
Summary
Insiders reported 1 buys worth $118,250.00 and 14 sells worth $8.61M over the last 12 months. That adds up to net selling of $8.49M. Liu Dongfang was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +64.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +64.1% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Nuvation Bio Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NUVB's management, answered from reported figures.
Who manages NUVB?
Nuvation Bio Inc. (NUVB) lists 10 active executives. The top listed executive is David C. Hanley, Chief Technical Operations Officer.
Are NUVB insiders buying or selling?
Recent insider activity shows net buying of $114.79M.
Continue the stock analysis
Jump to another research area for this company.